PerQseal® Clinical Study

NCT ID: NCT05653336

Last Updated: 2025-01-28

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 149 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-30
• Study Completion Date: 2025-06-30

Brief Summary

The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures.

Detailed Description

The objective of this pivotal study is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures, with sufficient rigor to provide robust scientific evidence for the demonstration of clinical safety and efficacy of the PerQseal closure system to support a pre-market approval submission.

Conditions

Percutaneous Large Hole Vascular Closure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Subjects implanted with PerQseal Vascular Closure Device

Subjects implanted with bioabsorbable implant to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.

Group Type: EXPERIMENTAL

PerQseal® Closure Device System

Intervention Type: DEVICE

Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.

Interventions

PerQseal® Closure Device System

Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 19 years,

2. Clinically indicated for a percutaneous arterial interventional catheter-based procedure, e.g., transcatheter aortic valve replacement/implantation (TAVR/TAVI) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aortic aneurysm repair (TEVAR), or use of a circulatory assist device or extracorporeal oxygenation using a common femoral arteriotomy created by a 12 to 22 F sheath (arteriotomy up to 26 F),

3. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements,

4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.

Exclusion Criteria

1. Evidence of current systemic bacterial or cutaneous infection, including groin infection,

2. Known bleeding diathesis, definite or potential coagulopathy, platelet count < 100,000/µl or subjects on long term anticoagulants with an INR > 2 within 12 hours prior to index procedure,

3. Significant anaemia (haemoglobin < 9 g/dL or haematocrit < 27%), within 24 hours prior to index procedure,

4. Known type II heparin-induced thrombocytopenia,

5. Documented left ventricular ejection fraction < 20%,

6. Ipsilateral or contralateral lower extremity amputation.

7. Claudication (Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral artery of target leg,

8. Known existing nerve damage in the target leg,

9. Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine > 2.5 mg/dL) or on renal replacement therapy,

10. Known allergy to any of the materials used in the PerQseal device (refer to Instructions for Use),

11. Subject unsuitable for surgical repair of the target leg access site,

12. Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90-days prior to index procedure,

13. Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for haemostasis, in the target leg, within the 90-days prior to index procedure,

14. Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for haemostasis in the target leg, within the 30-days prior to index procedure,

15. Evidence of marked tortuosity of the femoral or external iliac arteries in the target leg, based on pre-primary procedure CT angiography,

16. Evidence of arterial diameter stenosis > 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,

17. Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,

18. Target femoral artery diameter is less than 6 mm or 7 mm, depending on whether S (small) or L (large) PerQseal Introducer will be used for arteriotomy closure, respectively, based on pre-primary procedure CT angiography,

19. Further planned endovascular/catheter-based procedure in the target leg in the 30-days following the index procedure.

20. Subject is enrolled in another investigational medical device or drug study,

21. Subject has been previously enrolled in this clinical study.

22. Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19 within two weeks, or recent exposure to a person with COVID-19 infection within two weeks.

23. Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography).

24. Difficult dilation during initial target femoral artery access (e.g., that damages or kinks dilators) while step-dilating up to the large-bore device,

25. During arterial puncture, the target femoral artery suspected to have experienced a posterior arterial wall needle puncture or underwent > one needle puncture during the primary procedure (with a needle larger than a Micropuncture needle (> 21 gauge or > 0.819 mm diameter) )

26. Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm.,

27. Significant blood loss requiring transfusion of blood products during primary procedure or within 30-days prior to index procedure,

28. Activated clotting time (ACT) > 250 seconds immediately prior to sheath removal or if ACT measurements are expected to be > 250 seconds for more than 24 hours after index procedure,

29. Target puncture site is in a vascular graft,

30. Target arteriotomy greater than 26 F,

31. Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 15 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery,

32. Target arteriotomy located at the level or above the inferior epigastric artery and/or beneath or above the inguinal ligament based on bony/arterial landmarks (above femoral head on A-P projection),

33. Subjects with an acute haematoma > 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site identified intra-procedurally,

34. Evidence of bleeding around the primary procedure sheath (VARC type1/BARC type 2 or higher),

35. Intra-procedural angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal device,

36. Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) at the time of planned vascular closure,

37. Systolic blood pressure < 90 mmHg at the time of planned vascular closure.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vivasure Medical Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

William Gray, Dr.

Role: PRINCIPAL_INVESTIGATOR

Lankenau heart Institute

Sean Lyden, Dr.

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Locations

HonorHealth

Scottsdale, Arizona, United States

Scripps

La Jolla, California, United States

Northern Light Eastern Maine Medical Center

Bangor, Maine, United States

Cooper University Hospital

Camden, New Jersey, United States

The Valley Hospital

Paramus, New Jersey, United States

University of Buffalo

Buffalo, New York, United States

Columbia University Medical Center/ NewYork Presbyterian Hospital

New York, New York, United States

University of Rochester Medical Center

Rochester, New York, United States

Stony Brook University Hospital

Stony Brook, New York, United States

Montefiore Medical Center (multiple centers)

The Bronx, New York, United States

The Cleveland Clinic

Cleveland, Ohio, United States

UPMC Pinnacle Health

Mechanicsburg, Pennsylvania, United States

UPenn - Perelman Center for Advanced Medicine,

Philadelphia, Pennsylvania, United States

Lankenau Institute for Medical Research

Wynnewood, Pennsylvania, United States

The Texas Heart Institute

Houston, Texas, United States

St Franziskus Hospital

Münster, North Rhine-Westphalia, Germany

Leipzig University Hospital

Leipzig, Saxony, Germany

St. Gertrauden Krankenhaus (SGK)

Berlin, , Germany

Countries

United States; Germany

Other Identifiers

P696-00

Identifier Type: -

Identifier Source: org_study_id